Gara Jalqabaatti › Dhibee Qara › Virginia › Arlington
Qorannoo klinikaalii Dhibee Qara Arlington, VA keessatti
Qorannoo 41 Dhibee Qara f Arlington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Inova Fair Oaks Hospital, Fairfax · Miili 11 fagaatti
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Namoota walitti qabaa jiraSadarkaa 2
- Virginia Cancer Specialists (VCS) ( Site 0408), Fairfax · Miili 11 fagaatti
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of PHN-012 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- PHN-012-001 Site, Fairfax · Miili 11 fagaatti
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Inova Schar Cancer Infusion Pharmacy, Fairfax · Miili 11 fagaatti
- Inova Schar Cancer, Fairfax · Miili 11 fagaatti
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Research Site, Fairfax · Miili 11 fagaatti
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Namoota walitti qabaa jiraSadarkaa 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · Miili 11 fagaatti
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT - Virginia, Fairfax · Miili 11 fagaatti
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- USO-Virginia Cancer Specialists, PC, Fairfax · Miili 11 fagaatti
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- USO - Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · Miili 11 fagaatti
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology, Fairfax · Miili 11 fagaatti
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- Inova Schar Cancer Institute, Fairfax · Miili 11 fagaatti
- Inova Fair Oaks Hospital, Fairfax · Miili 11 fagaatti
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Fairfax · Miili 11 fagaatti
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Namoota walitti qabaa jiraSadarkaa 1/2
- Next Oncology Virginia, Fairfax · Miili 11 fagaatti
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology, Fairfax · Miili 11 fagaatti
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · Miili 5 fagaatti
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 2
- Inova Fairfax Hospital, Fairfax · Miili 11 fagaatti
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Qorannoo Dhibee Qara magaalota biroo keessatti
- Houston, TXQorannoo 78
- Boston, MAQorannoo 62
- New York City, NYQorannoo 60
- Los Angeles, CAQorannoo 45
- Washington, DCQorannoo 41
- Chicago, ILQorannoo 41
- Baltimore, MDQorannoo 40
- Nashville, TNQorannoo 40
- St. Louis, MOQorannoo 39
- Columbus, OHQorannoo 37
- Philadelphia, PAQorannoo 36
- Seattle, WAQorannoo 33
Qorannoo biroo Arlington keessatti
- Kansara Qara'a Non-Small CellQorannoo 104
- Kansara MetastatikiiQorannoo 53
- Kansarii ColorectalQorannoo 52
- Saree (Gosoota Hunda)Qorannoo 48
- Saree OljooQorannoo 47
- Kansarii OvariiQorannoo 46
- Kansa EndometiriyaaliiQorannoo 39
- Kansarii PancreasQorannoo 33
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 26
- Kansarii Hafuu Seli XiqqaaQorannoo 23
- Kanisa HarkaaQorannoo 20
- Kansaar Onnee Triple-NegativeQorannoo 20
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.